Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117572 · ClinicalTrials.gov registry record · Phase 3
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase 3 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
NCT00117572 is a Phase 3 study that has completed, run by University of Chicago. The registered enrollment target is 285 participants.
The verdict
NCT00117572, a Phase 3 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
Study Summary
The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer. Induction chemotherapy given before receiving local treatment has been shown to reduce the rate of distant failure. Many drugs have been found to prevent tumor cells from growing or dividing, although it has yet to be determined which agent, or specific combination of agents, is most effective in treating head and neck cancer. Docetaxel is a drug which has been reported to show promising activity in Phase II head and neck cancer studies. Therefore, the purpose of this trial is to compare the effectiveness of induction chemotherapy followed by chemoradiotherapy versus the same chemoradiotherapy alone in patients with locally advanced head and neck cancer.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG fluorouracil
- DRUG hydroxyurea
- PROCEDURE chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2004-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117572
The ClinicalTrials.gov registry entry for NCT00117572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00117572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117572 about?
NCT00117572 is a clinical study titled "Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)". The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer. Induction chemotherapy given before receiving local treatment has been shown to reduce the rate of distant f...
What is the current status of trial NCT00117572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2004-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00117572?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), fluorouracil (DRUG), hydroxyurea (DRUG), chemotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00117572?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.